Nonsteroidal antiinflammatory drugs and bladder cancer: A pooled analysis

American Journal of Epidemiology

Volumn 173, Issue 7, 2011, Pages 721-730

  Daugherty, Sarah E ^a   Pfeiffer, Ruth M ^a   Sigurdson, Alice J ^a   Hayes, Richard B ^b   Leitzmann, Michael ^c   Schatzkin, Arthur ^a   Hollenbeck, Albert R ^d   Silverman, Debra T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d AARP   (United States)

Author keywords

anti inflammatory agents, non steroidal; aspirin; meta analysis; urinary bladder neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; FENOPROFEN CALCIUM; IBUPROFEN; INDOMETACIN; KETOPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

CANCER; CONFIDENCE INTERVAL; DISEASE INCIDENCE; DRUG; HEALTH RISK; META-ANALYSIS; QUESTIONNAIRE SURVEY; REGRESSION ANALYSIS;

ARTICLE; BLADDER CANCER; CANCER RISK; CIGARETTE SMOKING; DRUG USE; HUMAN; INCIDENTAL FINDING; QUESTIONNAIRE; RISK REDUCTION; SEX DIFFERENCE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 79953836161     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq437     Document Type: Article

References (39)

1. Blumentals WA, Foulis PR, Schwartz SW, et al. Analgesic therapy and the prevention of bladder cancer. Urol Oncol. 2004;22(1):11-15. (Pubitemid 38542706)
2. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-ste-roidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000;82(7):1364-1369. (Pubitemid 30145360)
3. Fortuny J, Kogevinas M, Garcia-Closas M, et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1696-1702. (Pubitemid 44497106)
4. Genkinger JM, De Vivo I, Stampfer MJ, et al. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the Health Professionals Follow-Up Study. Int J Cancer. 2007; 120(10):2221-2225. (Pubitemid 46555862)
5. Sørensen HT, Friis S, Nørgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88(11):1687-1692. (Pubitemid 36760410)
6. Fortuny J, Kogevinas M, Zens MS, et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 2007;7:13. (doi:10.1186/ 1471-2490-7-13).
7. Steineck G, Wiholm BE, Gerhardsson de Verdier M. Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol. 1995;34(6):741-748.
8. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):47-55. (Pubitemid 41002838)
9. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320(7250):1642-1646. (Pubitemid 30364636)
10. Pommer W, Bronder E, Klimpel A, et al. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant. 1999;14(12): 2892-2897.
11. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989; 299(6710):1247-1250. (Pubitemid 19280046)
12. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138-146. (Pubitemid 24073387)
13. Friis S, Sørensen HT, McLaughlin JK, et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88(5): 684-688. (Pubitemid 36411444)
14. Ratnasinghe LD, Graubard BI, Kahle L, et al. Aspirin use and mortality from cancer in a prospective cohort study. Antican-cer Res. 2004;24(5B):3177- 3184. (Pubitemid 39390970)
15. Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci. 2008; 65(9):1295-1301.
16. Zha S, Yegnasubramanian V, Nelson WG, et al. Cyclooxyge-nases in cancer: progress and perspective. Cancer Lett. 2004;215(1):1-20.
17. Liebert M, Gebhardt D, Wood C, et al. Urothelial differentiation and bladder cancer. Adv Exp Med Biol. 1999;462: 437-448.
18. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 1999; 59(22):5647-5650.
19. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res. 2000;6(6): 2424-2430. (Pubitemid 30399211)
20. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res. 2001;7(3):558-561. (Pubitemid 32707978)
21. Grubbs CJ, Juliana MM, Eto I, et al. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res. 1993;13(1): 33-36. (Pubitemid 23118191)
22. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60(20):5599-5602.
23. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1998; 58(14):3028-3031. (Pubitemid 28335083)
24. Rao KV, Detrisac CJ, Steele VE, et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996; 17(7):1435-1438. (Pubitemid 26242647)
25. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001;154(12):1119-1125. (Pubitemid 33140635)
26. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000; 21(suppl 6):349S-355S.
27. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(suppl 6): 273S-309S.
28. Boice JD Jr, Mandel JS, Doody MM, et al. A health survey of radiologic technologists. Cancer. 1992;69(2):586-598.
29. Sigurdson AJ, Doody MM, Rao RS, et al. Cancer incidence in the US Radiologic Technologists Health Study, 1983-1998. Cancer. 2003;97(12):3080-3089. (Pubitemid 36676264)
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. (Pubitemid 34746062)
31. Barbieri SS, Weksler BB. Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J. 2007;21(8):1831-1843. (Pubitemid 46855629)
32. Nakao S, Ogata Y, Sugiya H. Nicotine stimulates the expression of cyclooxygenase-2 mRNA via NFkappaB activation in human gingival fibroblasts. Arch Oral Biol. 2009;54(3): 251-257.
33. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-615. (Pubitemid 47073542)
34. Khwaja F, Allen J, Lynch J, et al. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res. 2004;64(17): 6207-6213. (Pubitemid 39129422)
35. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Onco-gene. 2004;23(57):9247-9258. (Pubitemid 40069695)
36. Slatore CG, Au DH, Littman AJ, et al. Association of non-steroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1203-1207.
37. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007; 99(11):881-889. (Pubitemid 47073510)
38. Pit SW, Byles JE, Cockburn J. Accuracy of telephone self-report of drug use in older people and agreement with pharmaceutical claims data. Drugs Aging. 2008;25(1): 71-80.
39. West SL, IPSE. A comparison of data sources for drug exposure ascertainment in pharmacoepidemiologic studies with emphasis on self-reported information. Pharmacoepidemiol Drug Saf. 1997;6(3):215-218. (Pubitemid 27304256)